Trial Profile
RICE Trial: Rifaximin In Chronic Hepatic Encephalopathy - A Randomized, Controlled Trial
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 18 Sep 2019
Price :
$35
*
At a glance
- Drugs Rifaximin (Primary) ; Lactulose
- Indications Hepatic encephalopathy
- Focus Therapeutic Use
- Acronyms RICE
- 27 Aug 2019 Status changed from recruiting to discontinued.
- 13 Jul 2018 According to a Bausch Health Companies media release, Valeant Pharmaceuticals International changed its name to Bausch Health Companies.
- 20 Nov 2015 New trial record